ATTENTION BCYC Investors: Securities Fraud Investigation Underway - Contact Levi & Korsinsky

Core Insights - Bicycle Therapeutics plc is under investigation for possible violations of federal securities laws, as announced by Levi & Korsinsky [1] - RBC Capital Markets downgraded Bicycle Therapeutics from Outperform to Sector Perform due to delays in the development of its drug, zelenectide pevedotin, which is intended for metastatic urothelial cancer [2] - Following the downgrade, Bicycle's American Depositary Receipt (ADR) price dropped over 7% on the same day [3] Company Developments - The delay in the drug's development is attributed to the decision to push dose selection to the first quarter of 2026, which raises concerns about increased competition in the urothelial cancer treatment market [2] - The competitive landscape is highlighted by the potential impact of a competing product from Pfizer, which may benefit from any further delays in Bicycle's drug development [2] Legal Context - Levi & Korsinsky LLP has a strong reputation in securities litigation, having secured significant settlements for shareholders and being recognized as one of the top firms in the United States for securities class actions [4]